Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

Naropin: Full Drug Profile

Medically reviewed by Min Clinic Staff | Updated: January 2026

Naropin - General Information

Naropin is a local anaesthetic drug belonging to the amino amide group. The name ropivacaine refers to both the racemate and the marketed S-enantiomer. Naropin hydrochloride is commonly marketed by AstraZeneca under the trade name Naropin. [Wikipedia]

 

Pharmacology of Naropin

Naropin, a local anesthetic agent, is indicated for the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures.

 

Naropin for patients

When appropriate, patients should be informed in advance that they may experience temporary loss of sensation and motor activity in the anesthetized part of the body following proper administration of lumbar epidural anesthesia. Also, when appropriate, the physician should discuss other information including adverse reactions in the Naropin package insert.

 

Naropin Interactions

Ropivacaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive. Cytochrome P4501A2 is involved in the formation of 3-hydroxy ropivacaine, the major metabolite. In vivo, the plasma clearance of ropivacaine was reduced by 70% during coadministration of fluvoxamine (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor. Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. Caution should be exercised when CYP1A2 inhibitors are coadministered. Possible interactions with drugs known to be metabolized by CYP1A2 via competitive inhibition such as theophylline and imipramine may also occur. Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.

 

Naropin Contraindications

Ropivacaine is contraindicated in patients with a known hypersensitivity to ropivacaine or to any local anesthetic agent of the amide type.

 

Additional information about Naropin

Naropin Indication

Used in obstetric anesthesia and regional anesthesia for surgery.

Mechanism Of Action
Local anesthetics such as Naropin block the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination and conduction velocity of affected nerve fibers.
Generic Name
Ropivacaine
Synonyms
Ropivacaina [INN-Spanish]; Ropivacainum [INN-Latin]; Ropivacaine [INN]; Ropivacaina [Spanish]; S-Ropivacaine
Drug Category
Anesthetics; Local Anesthetics
Drug Type
Small Molecule; Approved
Other Brand Names containing Ropivacaine
Naropin;
Absorption
Bioavailability is 87%–98% following epidural administration.
Toxicity (Overdose)
Systemic exposure to excessive quantities of ropivacaine mainly result in central nervous system (CNS) and cardiovascular effects – CNS effects usually occur at lower blood plasma concentrations and additional cardiovascular effects present at higher concentrations, though cardiovascular collapse may also occur with low concentrations. CNS effects may include CNS excitation (nervousness, tingling around the mouth, tinnitus, tremor, dizziness, blurred vision, seizures) followed by depression (drowsiness, loss of consciousness, respiratory depression and apnea). Cardiovascular effects include hypotension, bradycardia, arrhythmias, and/or cardiac arrest – some of which may be due to hypoxemia secondary to respiratory depression.
Protein Binding
94%, mainly to a1-acid glycoprotein
Biotransformation
Hepatic
Half Life
Approximately 4.2 hours.
Dosage Forms of Naropin
Solution Epidural
Chemical IUPAC Name
N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide
Chemical Formula
C17H26N2O
Organisms Affected
Humans and other mammals